+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06860334

UMIT-2 An Adaptive Phase IIb Trial Testing Favipiravir and Ribavirin Versus Standard Care for Crimean-Congo Hemorrhagic Fever in Turkey and Iraq

Led by Liverpool School of Tropical Medicine · Updated on 2026-08-07

378

Participants Needed

3

Research Sites

35 weeks

Total Duration

AI-Summary

What This Trial Is About

Crimean-Congo Hemorrhagic Fever CCHF is a viral disease affecting regions in Asia, the Middle East, South-Eastern Europe, and Africa, with Turkiye being a major center reporting over 1000 cases annually. Since 2002, management of CCHF has relied on optimized supportive care, but therapeutic options lack solid evidence. The UMIT-2 trial is a Phase IIb adaptive platform study conducted in multiple sites across Turkiye and Iraq, aiming to evaluate new antiviral treatments for CCHF with flexible interim monitoring to add or stop treatment arms based on early results. Participants will be randomly assigned in equal proportions to receive one of three treatments Favipiravir intravenous and oral, Ribavirin intravenous and oral, or optimized standard care according to national guidelines. Favipiravir is administered with a high initial dose intravenously followed by oral doses up to 7 days or until hospital discharge. Ribavirin is given with a loading intravenous dose followed by intravenous and oral doses for up to 7 days or until discharge. Standard care includes supportive therapies but excludes the investigational drugs. The study allows adding or removing treatment arms based on ongoing results and enrollment is determined by specific eligibility criteria. Participants will be hospitalized and monitored closely during treatment, with assessments including viral load measurements on day 5, safety and tolerability up to day 29, and clinical outcomes like time to hospital discharge and mortality. Pharmacokinetics of the drugs will also be studied. Data on additional supportive treatments will be recorded. The total study duration includes treatment and follow-up periods up to 29 days from treatment start. This trial aims to provide evidence on antiviral effects and safety of the studied treatments in CCHF patients.

CONDITIONS

Brief Title

UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF

Research Team

A

Alex Hainsworth

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here